[Natalizumab in multiple sclerosis].
Cecília
C
Rajda
Krisztina
K
Bencsik
László
L
Vécsei
D000465:Algorithms; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D002464:Cell Migration Inhibition; D000075202:Contraindications; D003937:Diagnosis, Differential; D005062:European Union; D006801:Humans; D039441:Integrin alpha4 / Q000187:drug effects; D007968:Leukoencephalopathy, Progressive Multifocal / Q000139:chemically induced / Q000175:diagnosis; D009103:Multiple Sclerosis / Q000175:diagnosis / Q000188:drug therapy*; D000069442:Natalizumab; D012008:Recurrence
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069442:Natalizumab; D039441:Integrin alpha4